Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Big effect

Adding a probiotic cut diarrhea risk by 55% in a meta-analysis of 2,054 people on H. pylori treatment — but the evidence can't say which specific strain was responsible.

This is one of the first meta-analyses to show a large, statistically robust reduction in a common antibiotic side effect, but because the analysis lumped together many different probiotic strains without isolating Bifidobacterium breve Bb-18's unique contribution, the finding is a promising signal rather than a prescription.

A meta-analysis of 13 randomized trials found that adding Lactobacillus probiotics to standard H. pylori therapy reduced the risk of diarrhea by 55% (a relative risk of 0.45), an unusually large effect for a probiotic intervention. However, the same review found no benefit for vomiting, abdominal pain, or constipation, and it could not pinpoint which specific probiotic strains or doses produced the effect — so the headline result comes with a major caveat about precision.

Where this fits in the evidence

This is among the first studies we've indexed on Bifidobacterium breve Bb-18 for Reduced Diarrhea — treat it as an early signal until more research accumulates.

This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.

Back to top